Edward Tenthoff

Ted Tenthoff is a managing director and senior research analyst at Piper Sandler, focused on the drug discovery sector of the biotech industry. In April 2013 and 2015, Tenthoff moderated panels at the International Adult Stem Cell Conference at the Vatican. He was ranked No. 2 stock picker in biotechnology by the 2012 Wall Street Journal "Best on the Street" survey and was ranked No. 1 stock picker for the life science tools and services sector in the 2006 Starmine Analyst Awards. Prior to joining Piper Sandler in 2003, he covered the genomics sector at Robertson Stephens & Company, and was a medical technology analyst at Lehman Brothers. Tenthoff received a bachelor’s degree in international relations from the University of Pennsylvania.

Universe Coverage

Biotechnology
ASLN	Aslan Pharmaceuticals Ltd.
NXTC	NextCure, Inc.
SYRS	Syros Pharmaceuticals, Inc.
ARVN	Arvinas Inc.
OPK	OPKO Health, Inc.
MCRB	Seres Therapeutics, Inc.
FULC	Fulcrum Therapeutics, Inc.
GMDA	Gamida Cell Ltd.
BCYC	Bicycle Therapeutics Ltd.
FATE	Fate Therapeutics, Inc.
DYN	Dyne Therapeutics, Inc.
XNCR	Xencor, Inc.
KYMR	Kymera Therapeutics, Inc.
ARWR	Arrowhead Pharmaceuticals
ALNY	Alnylam Pharmaceuticals, Inc.
CCXI	ChemoCentryx, Inc.
MIST	Milestone Pharmaceuticals, Inc.
MRNA	Moderna, Inc.
STRO	Sutro Biopharma, Inc.
CRSP	CRISPR Therapeutics AG
PSTX	Poseida Therapeutics, Inc.
KRON	Kronos Bio, Inc.
RAPT	Rapt Therapeutics, Inc.
TPST	Tempest Therapeutics, Inc.
APTO	Aptose Biosciences, Inc.
IPSC	Century Therapeutics, Inc.
GLUE	Monte Rosa Therapeutics, Inc.
PNT	POINT Biopharma Global Inc.
OMGA	Omega Therapeutics, Inc.
LEGN	Legend Biotech Corporation
MESO	Mesoblast Ltd.
GRTS	Gritstone bio, Inc.
CUE	Cue Biopharma, Inc.
XFOR	X4 Pharmaceuticals, Inc.
GRTX	Galera Therapeutics, Inc.